[ Price : $8.95]
Four Ropes & Gray attorneys identify the key provisions in three new FDA clinical trial modernization guidances.[ Price : $8.95]
Federal Register notice: FDA determines for patent extension purposes the regulatory review period for SpringWorks Therapeutics Og...[ Price : $8.95]
Pfizer withdraws its sickle cell disease drug Oxbryta from all approved markets after data show the overall benefit does not outwe...[ Price : $8.95]
Three stakeholder organizations make comments and suggestions for changes in an FDA draft guidance on diversity action plans to in...[ Price : $8.95]
FDA lifts a clinical hold on Biomea Fusions Phase 1-2 clinical trials of its investigational covalent menin inhibitor BMF-219 in T...[ Price : $8.95]
Investigative journalists write in BMJ about FDA advisory committee members financial conflicts of interest in the consideration o...[ Price : $8.95]
Bayer submits a supplemental NDA for oral androgen receptor inhibitor Nubeqa (darolutamide), seeking approval for its use in combi...[ Price : $8.95]
The FDA Oncology Drugs Advisory Committee votes not to recommend using immune checkpoint inhibitors in first-line advanced gastric...